Novo Nordisk halves US price of weight-loss drug as obesity trial confirms weight loss
Aggressive US pricing and new trial data mark an escalating fight for share in the GLP-1 obesity market.
BusinessWorld Online · +14 outlets
Teva wins FDA approval for WELTRUZA, first once-monthly subcutaneous olanzapine for schizophrenia
The injectable extends Teva's branded neuro-psychiatry franchise and offers schizophrenia patients a monthly subcutaneous alternative to existing olanzapine reg
Globes · +13 outlets
Pfizer to halt development of closely watched weight-loss drug
The retreat narrows the field of late-stage obesity contenders and marks a setback for Pfizer's metabolic pipeline.
Olhar Digital · +12 outlets
Teva introduces first generic GLP-1 weight-loss drug as Canada authorizes copy
Generic entry pressures branded GLP-1 pricing and signals a new phase of competition in obesity and diabetes care.
BusinessWorld Online · +7 outlets
Wall Street pulls back on weight-loss drug hype as Trump weighs in on prices
Investor enthusiasm cools as policy attention turns to obesity drug costs and Medicare coverage questions.
BusinessWorld Online · +1 outlets
BridgeBio reports positive Phase 3 encaleret data in ADH1, doses first patient in hypoparathyroidism study
The rare-disease readouts keep BridgeBio's pipeline moving across two calcium-disorder indications with distinct regulatory paths.
Quiver Quantitative · +8 outlets
Travere Therapeutics wins FDA approval for drug in rare kidney disease
The clearance gives Travere a second commercial product in a niche renal indication with few approved options.
Stocktwits · +12 outlets
Capricor's DMD therapy gets Lancet backing ahead of FDA decision
Peer-reviewed publication and 24-month data strengthen Capricor's case ahead of a make-or-break regulatory ruling on its Duchenne therapy.
Stocktwits · +3 outlets
Tecentriq plus chemotherapy wins approval for Stage III dMMR colon cancer
The regimen halves recurrence or death risk in an early-stage colon cancer setting, expanding immunotherapy into adjuvant use.
inkl · +14 outlets
Roche reports vamikibart vision gains through week 52 in two trials
The yearlong data support Roche's experimental therapy for uveitic macular edema, where about 20% of patients can progress to lasting blindness.
Mugglehead Investment Magazine · +6 outlets
Compass Therapeutics hits primary endpoint in Phase 3 treatment-resistant depression trial, CMPS jumps 23%
A positive pivotal readout would open a large, poorly served psychiatric indication for the company's antibody candidate.
Stocktwits · +11 outlets
AbbVie's RINVOQ shows 93.3% clinical and steroid-free remission in Crohn's patients with fistulas
The data support expanded use of RINVOQ in a difficult-to-treat Crohn's subpopulation.
Stock Titan
Hanmi Pharm's domestic obesity drug Epe could cost a third of rivals
A cheaper Korean obesity therapy could disrupt a market estimated at $1.5 billion with aggressive local pricing.
헤럴드경제 · +2 outlets
HLB completes FDA resubmission for first-line liver cancer treatment
The resubmission restarts the regulatory clock for HLB's liver cancer candidate after an earlier setback.
아시아경제 · +5 outlets
Obesity drug competition shifts focus to quality of weight loss
As new GLP-1 entrants crowd the market, developers are differentiating on lean-mass preservation and quality of weight loss.
조선일보 · +13 outlets
Supernus Pharmaceuticals wins FDA approval for ONAPGO
The approval adds a new commercial asset to Supernus as investors weigh the revenue ramp.
Simply Wall Street · +8 outlets
Novartis pairs first-in-class FDA clearance with 46 upcoming MS abstracts
Novartis is positioning a fresh approval alongside a broad multiple sclerosis data slate.
ad-hoc-news.de
Mark Cuban's Cost Plus Drugs teams with Humana on employer drug costs
The tie-up targets prescription costs for employers and adds a payer partnership to the transparency-focused online pharmacy.
Medical Economics · +1 outlets